Kyverna Therapeutics (KYTX) Equity Ratio (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Equity Ratio data on file, last reported at 0.76 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 11.46% year-over-year to 0.76; the trailing twelve-month figure through Mar 2026 stood at 0.76 (down 11.46% YoY), and the FY2025 full-year result was 0.79, down 9.66% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.76, down from 0.79 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.93 in Q1 2024 and bottomed at 0.17 in Q4 2023.
• The 4-year median for Equity Ratio is 0.84 (2025), against an average of 0.75.
• The widest annual swing landed in 2024, when Equity Ratio surged 600.81%; it then declined 11.46% in 2026.
• A 4-year view of Equity Ratio shows it stood at 0.17 in 2023, then soared by 600.81% to 0.88 in 2024, then dropped by 9.66% to 0.79 in 2025, then fell by 3.74% to 0.76 in 2026.
• The last three Equity Ratio figures came in at 0.76 (Q1 2026), 0.79 (Q4 2025), and 0.81 (Q3 2025), per Business Quant data.

Peer Comparison